自分泌信号
旁分泌信号
间质细胞
癌症研究
CXCR4型
肿瘤微环境
结直肠癌
肿瘤进展
癌相关成纤维细胞
癌症
癌症干细胞
生物
趋化因子受体
医学
趋化因子
趋化因子受体
内科学
受体
肿瘤细胞
作者
Chao-Yang Chen,Shih-Hsien Yang,Ping-Ying Chang,Sufeng Chen,Shin Nieh,Wen-Yen Huang,Yu‐Chun Lin,Oscar K. Lee
出处
期刊:Cells
[Multidisciplinary Digital Publishing Institute]
日期:2024-08-12
卷期号:13 (16): 1334-1334
被引量:2
标识
DOI:10.3390/cells13161334
摘要
Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide, and cancer-associated fibroblasts (CAFs) play a major role in the tumor microenvironment (TME), which facilitates the progression of CRC. It is critical to understand how CAFs promote the progression of CRC for the development of novel therapeutic approaches. The purpose of this study was to understand how CAF-derived stromal-derived factor-1 (SDF-1) and its interactions with the corresponding C-X-C motif chemokine receptor 4 (CXCR4) promote CRC progression. Our study focused on their roles in promoting tumor cell migration and invasion and their effects on the characteristics of cancer stem cells (CSCs), which ultimately impact patient outcomes. Here, using in vivo approaches and clinical histological samples, we analyzed the influence of secreted SDF-1 on CRC progression, especially in terms of tumor cell behavior and stemness. We demonstrated that CAF-secreted SDF-1 significantly enhanced CRC cell migration and invasion through paracrine signaling. In addition, the overexpression of SDF-1 in CRC cell lines HT29 and HCT-116 triggered these cells to generate autocrine SDF-1 signaling, which further enhanced their CSC characteristics, including those of migration, invasion, and spheroid formation. An immunohistochemical study showed a close relationship between SDF-1 and CXCR4 expression in CRC tissue, and this significantly affected patient outcomes. The administration of AMD3100, an inhibitor of CXCR4, reversed the entire phenomenon. Our results strongly suggest that targeting this signaling axis in CRC is a feasible approach to attenuating tumor progression, and it may, therefore, serve as an alternative treatment method to improve the prognosis of patients with CRC, especially those with advanced, recurrent, or metastatic CRC following standard therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI